Life Sciences Series: Venture Spotlight: Planning for Exit
Pipelines of large pharma and bio-pharma companies are not meeting current demands and patent expirations over the next few years will significantly impact branded sales. Large medical device manufactures have also struggled to release new and innovative products that will drive revenue growth. These dynamics, combined with large cash reserves and a recovery in the equity markets, have created M&A opportunities for life science companies at varying stages of development and opened the capital markets window slightly.
Decisions a company makes early in the development process can impact future exit opportunities.
- Will a strategic investor influence potential acquirers?
- What are the trade-offs to licensing intellectual property to fund development?
- When and how should a company approach potential acquirers?
A panel of seasoned VC investors and life science executives who have recently navigated a successful exit will discuss the current state of the life science M&A and IPO markets and the tradeoffs between the two, when and how companies and investors should evaluate exit opportunities, key deal terms that are heavily negotiated in exit transactions and the venture capitalists’ role in the exit process.
Latham & Watkins
Albert Cha, M.D., Ph.D.
Jonathan MacQuitty, PhD
Advanced Technology Ventures
Planning for Exit
|When:||Thursday, September 15, 2011
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
|Where:||South San Francisco Conference Center
255 South Airport Blvd.
South San Francisco, CA
|Parking:||Multiple Lot Options|
|Getting There:||Public Transportation Information|
|Cost:||Pre-registration through September 14
$20 BayBio Members
On-site registration on September 15
$40 BayBio Members
|Attire:||Business attire suggested|